Cognition Therapeutics Inc (CGTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.03-1.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CGTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CGTX — debt issuance
Dated 2025-12-18
Entry into a Material Definitive Agreement. On December 18, 2025, Cognition Therapeutics, Inc. (the “ Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company may sell, from time to time, at its option, shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), through or to Jefferies, as sales agent or principal (the “ATM Offering”). Pursuant to the prospectus sup…
Why it matters: Top results will guide future plans for zervimesine in Alzheimer's disease. Good results could help investors feel more confident.
Watch forTopline results from the Phase 2 START trial show positive efficacy signals.
Also watch forTop results show no big problems with efficacy or safety.
Why it matters: Maintaining cash reserves is vital for funding ongoing operations and trials. A decline could signal financial distress.
Worry ifCash and equivalents stay steady or grow. This shows enough funding until Q2 2027.
Less concerning ifCash reserves fall a lot, showing a possible funding problem.
Why it matters: Positive FDA feedback would confirm the trial design for zervimesine in DLB psychosis. This could support the drug's path to approval.
Supportive ifFDA confirms that psychosis in DLB is an approvable outcome and aligns on trial design.
Worry ifThe FDA has big concerns about the trial design or endpoints.
Why it matters: Watching cash burn helps us see if the company can pay its bills until Q2 2027.
Worry ifOperating losses decrease to less than negative $8M in Q2 2026.
Less concerning ifOperating losses increase beyond negative $10M in Q2 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$277 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $838 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,722 loss on $10,000 · 77.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Better losses mean better financial health and efficiency. This can help investor confidence.
Supportive ifOperating losses drop below negative $8.8M in Q1 2026.
Worry ifOperating losses increase beyond negative $8.8M in Q1 2026.
Why it matters: Positive FDA feedback would confirm the trial design for zervimesine in DLB psychosis. This is key for future approval.
Supportive ifFDA confirms that DLB psychosis is an approvable outcome and aligns on trial design.
Worry ifThe FDA has concerns about the trial design or endpoints for DLB psychosis.
Why it matters: Updates on cash runway are critical for funding ongoing operations and trials. Insufficient cash could hinder progress.
Worry ifManagement says cash runway lasts until Q2 2027 without needing more funding.
Less concerning ifManagement says cash runway is shorter than expected or needs new funding.
Why it matters: Starting the Phase 3 trial is crucial for zervimesine's path to market. It signals progress in treating DLB psychosis.
Supportive ifThe company announces the start of the Phase 3 trial for zervimesine in DLB psychosis.
Worry ifThe trial start is delayed beyond mid-2027 or is canceled.
Why it matters: The main results will guide future work on zervimesine for Alzheimer's disease. Positive results could benefit investors.
Watch forTopline results from the Phase 2 START trial show zervimesine works well in Alzheimer's.
Also watch forTopline results show zervimesine does not work well in Alzheimer's.